ATXA Therapeutics receives Funding through the European Innovation Council Accelerator Programme

ATXA Therapeutics Limited (ATXA) is delighted to announce that it is honoured to receive grant and equity funding through the prestigious...

ATXA Presentation at ERS International Congress 2022

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH)...

European Commission publish article on ATXA's PAH-HOPE project

The EU Commission has published a "Results in Brief" article on ATXA Therapeutics' EU-funded PAH-HOPE project. Entitled "New Hope for...

ATXA Presentation at ESC Congress 2021

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for treatment of PAH at the European Society of Cardiology...

Newly-published preclinical findings for ATXA Therapeutics' NTP42

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a further preclinical model of...

World Orphan Drug Virtual Conference

Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on...

Jonathan Langley Appointment

ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience...

ATXA Therapeutics looks to raise $30m to secure regulatory approval

https://www.irishtimes.com/business/technology/atxa-therapeutics-looks-to-raise-30m-to-secure-regulatory-approval-1.4314023

Publication of preclinical findings for ATXA Therapeutics' NTP42

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary...

100 Hot Start Ups.

The companies driving Ireland's entrepreneurial edge. ATXA Therapeutics Ltd is delighted to be recognised amongst such a fantastic list...

ATXA & PAH- Hope attend ERS Congress 2019 in Madrid

We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please...

COMPANY UPDATES